MARKET

MIRA

MIRA

Mira Pharma
NASDAQ
0.8163
-0.0253
-3.01%
After Hours: 0.8050 -0.0113 -1.38% 19:34 07/30 EDT
OPEN
0.8510
PREV CLOSE
0.8416
HIGH
0.8968
LOW
0.8000
VOLUME
68.67K
TURNOVER
--
52 WEEK HIGH
2.450
52 WEEK LOW
0.8000
MARKET CAP
34.30M
P/E (TTM)
-0.5661
1D
5D
1M
3M
1Y
5Y
1D
Mira Pharmaceuticals provides update on MIRA-55, SKNY-1
TipRanks · 12h ago
Mira Pharmaceuticals advances MIRA-55 toward IND-enabling studies after completing exploratory tox dosing in rats, dogs
PUBT · 13h ago
Weekly Report: what happened at MIRA last week (0720-0724)?
Weekly Report · 3d ago
Weekly Report: what happened at MIRA last week (0713-0717)?
Weekly Report · 07/20 09:34
Weekly Report: what happened at MIRA last week (0706-0710)?
Weekly Report · 07/13 09:34
MIRA Pharmaceuticals announces positive preclinical results for MIRA-55
TipRanks · 07/10 12:29
Mira Pharmaceuticals reports formulation results for MIRA-55
TipRanks · 07/10 12:11
MIRA Pharma Announces Results Preclinical Studies Evaluating Optimized Oral Formulations Of MIRA-55, Oral Drug Candidate Being Developed As Non-Opioid Therapy For Chronic Inflammatory Pain
Benzinga · 07/10 12:03
More
About MIRA
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.

Webull offers Mira Pharmaceuticals Inc stock information, including NASDAQ: MIRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MIRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MIRA stock methods without spending real money on the virtual paper trading platform.